import { Helmet } from "@/compat/react-helmet-async";
import { Link } from "@/compat/react-router-dom";
import Navigation from "@/components/Navigation";
import Footer from "@/components/Footer";
import { Button } from "@/components/ui/button";
import { Card } from "@/components/ui/card";
import { ArrowLeft, Calendar, Clock, AlertCircle, TrendingDown } from "lucide-react";
import { getBlogPostMeta } from "@/utils/getBlogPostMeta";
import ogImage from "@/assets/og/semaglutide-for-diabetes.jpg";
import { SocialShare } from "@/components/blog/SocialShare";
import { TableOfContents } from "@/components/blog/TableOfContents";
import { AuthorBio } from "@/components/blog/AuthorBio";
import { LastUpdated } from "@/components/blog/LastUpdated";
import { MedicalReview } from "@/components/blog/MedicalReview";
import { PeopleAlsoRead } from "@/components/blog/PeopleAlsoRead";
import { getPeopleAlsoRead } from "@/utils/blogLinks";
import { QAPageSchema } from "@/components/seo/QAPageSchema";
import { ContentFreshnessIndicator } from "@/components/ContentFreshnessIndicator";
import { getModifiedDate } from "@/utils/getModifiedDate";
import { TopicClusterNav } from "@/components/blog/TopicClusterNav";
import { getClusterNavigation } from "@/utils/relatedContent";

const SemaglutideForDiabetes = () => {
  const postMeta = getBlogPostMeta("semaglutide-for-diabetes");
  const publishDate = postMeta?.date || "2025-02-08";
  const modifiedDate = getModifiedDate('semaglutide-for-diabetes', publishDate);
  const readTime = postMeta?.readTime || "15 min";
  const clusterNav = getClusterNavigation('semaglutide-for-diabetes');
  
  const qaData = [
    {
      question: "Is semaglutide better than metformin for type 2 diabetes?",
      answer: "Semaglutide often provides superior A1C reduction (1.5-1.8% vs 1.0-1.5% for metformin) plus significant weight loss (15-20 lbs on average). However, metformin is typically first-line due to lower cost and oral administration. Many people take both together for optimal results."
    },
    {
      question: "How much does semaglutide lower A1C in diabetics?",
      answer: "Clinical trials show semaglutide reduces A1C by 1.5-1.8% on average at the 1.0mg dose for diabetes. Starting A1C matters - those with A1C above 9% often see 2-2.5% reductions. About 70-80% of patients reach A1C below 7% (treatment target) within 6 months."
    },
    {
      question: "Can semaglutide cure type 2 diabetes?",
      answer: "Semaglutide cannot cure diabetes, but it can put it into remission when combined with significant weight loss and lifestyle changes. Studies show 30-40% of patients achieve diabetes remission (A1C < 6.5% off medications) after losing 15%+ body weight. However, diabetes typically returns if medication is stopped without maintaining weight loss."
    },
    {
      question: "What's the difference between Ozempic and Wegovy?",
      answer: "Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (doses up to 2mg). Wegovy is approved for weight loss (2.4mg dose). The medications work identically - the only differences are indication and maximum dose. Many doctors prescribe Ozempic off-label for weight loss."
    }
  ];
  
  return (
    <>
      <QAPageSchema 
        questions={qaData}
        mainEntityName="Semaglutide for Type 2 Diabetes"
      />
      <Helmet>
        <title>Semaglutide for Type 2 Diabetes: Blood Sugar Control & Weight Loss | Trimi</title>
        <meta name="description" content="Comprehensive guide to using semaglutide (Ozempic, Rybelsus) for type 2 diabetes management. Learn about blood sugar control, A1C reduction, dosing, and cardiovascular benefits." />
        <meta name="keywords" content="semaglutide diabetes, ozempic diabetes, semaglutide type 2 diabetes, semaglutide blood sugar, semaglutide A1C, ozempic type 2 diabetes, semaglutide insulin" />
        <meta name="author" content="Trimi Medical Team" />
        <link rel="canonical" href="https://trytrimi.com/blog/semaglutide-for-diabetes" />
        
        <meta property="og:title" content="Semaglutide for Type 2 Diabetes: Blood Sugar Control & Weight Loss" />
        <meta property="og:description" content="Comprehensive guide to using semaglutide for type 2 diabetes management, including blood sugar control and cardiovascular benefits." />
        <meta property="og:type" content="article" />
        <meta property="og:url" content="https://trytrimi.com/blog/semaglutide-for-diabetes" />
        <meta property="og:image" content={ogImage} />
        <meta property="article:published_time" content="2025-02-08T09:00:00Z" />
        <meta property="article:author" content="Trimi Medical Team" />
        <meta property="article:section" content="Diabetes Management" />
        <meta name="twitter:card" content="summary_large_image" />
        <meta name="twitter:image" content={ogImage} />
        
        <script type="application/ld+json">
          {JSON.stringify({
            "@context": "https://schema.org",
            "@type": "MedicalWebPage",
            "headline": "Semaglutide for Type 2 Diabetes: Blood Sugar Control & Weight Loss",
            "description": "Comprehensive guide to using semaglutide for type 2 diabetes management",
            "datePublished": "2025-02-08T09:00:00Z",
            "dateModified": "2025-02-08T09:00:00Z",
            "author": {
              "@type": "Organization",
              "name": "Trimi Medical Team"
            },
            "mainEntity": {
              "@type": "MedicalCondition",
              "name": "Type 2 Diabetes",
              "possibleTreatment": {
                "@type": "MedicalTherapy",
                "name": "Semaglutide"
              }
            }
          })}
        </script>
      </Helmet>

      <Navigation />

      <main className="min-h-screen bg-gradient-to-b from-background to-muted/20">
        <article className="container max-w-4xl mx-auto px-4 py-12">
          <Link to="/blog" className="inline-flex items-center text-primary hover:text-primary/80 mb-8 transition-colors">
            <ArrowLeft className="mr-2 h-4 w-4" />
            Back to Blog
          </Link>

          <header className="mb-12">
            <h1 className="text-4xl md:text-5xl font-bold mb-6 bg-gradient-to-r from-primary via-primary/80 to-primary bg-clip-text text-transparent">
              Semaglutide for Type 2 Diabetes: Comprehensive Management Guide
            </h1>
            
            <LastUpdated 
              publishDate={publishDate}
              modifiedDate={modifiedDate}
            />

            <p className="text-xl text-muted-foreground leading-relaxed">
              Semaglutide has revolutionized type 2 diabetes treatment, offering superior blood sugar control, significant weight loss, and cardiovascular protection. Learn how this medication can transform diabetes management.
            </p>
          </header>

          <MedicalReview 
            reviewerName="Dr. Michael Chen"
            credentials="MD, Board Certified in Endocrinology"
            specialty="Diabetes and Metabolic Health"
            reviewDate={modifiedDate}
          />

          <div className="prose prose-lg max-w-none space-y-8">
            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">What Makes Semaglutide Different for Diabetes?</h2>
              <p className="text-muted-foreground leading-relaxed">
                Semaglutide belongs to the GLP-1 receptor agonist class, originally developed specifically for type 2 diabetes before being approved for weight loss. Unlike older diabetes medications that simply lower blood sugar, semaglutide works through multiple complementary mechanisms that address the core problems of diabetes.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                The medication mimics GLP-1, a naturally occurring hormone that your body produces after eating. In people with type 2 diabetes, GLP-1 response is often impaired. Semaglutide essentially restores this natural regulatory system, helping your body manage blood sugar the way it should.
              </p>
            </section>

            <Card className="p-6 bg-primary/5 border-primary/20">
              <h3 className="text-xl font-semibold mb-4 flex items-center text-foreground">
                <TrendingDown className="mr-2 h-5 w-5 text-primary" />
                Expected A1C Reductions with Semaglutide
              </h3>
              <div className="space-y-3 text-muted-foreground">
                <div className="flex justify-between border-b border-border pb-2">
                  <span className="font-medium">0.5 mg dose:</span>
                  <span>-1.0% to -1.4% reduction</span>
                </div>
                <div className="flex justify-between border-b border-border pb-2">
                  <span className="font-medium">1.0 mg dose:</span>
                  <span>-1.4% to -1.8% reduction</span>
                </div>
                <div className="flex justify-between">
                  <span className="font-medium">2.0 mg dose:</span>
                  <span>-1.8% to -2.1% reduction</span>
                </div>
              </div>
              <p className="text-sm text-muted-foreground mt-4 italic">
                *Based on SUSTAIN clinical trial data. Individual results vary based on baseline A1C and adherence.
              </p>
            </Card>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">How Semaglutide Works for Diabetes</h2>
              
              <h3 className="text-2xl font-semibold mb-3 text-foreground">1. Glucose-Dependent Insulin Secretion</h3>
              <p className="text-muted-foreground leading-relaxed">
                Semaglutide stimulates your pancreas to release insulin, but only when blood sugar is elevated. This glucose-dependent mechanism means it won't cause hypoglycemia (dangerously low blood sugar) when used alone—a significant advantage over medications like sulfonylureas or insulin.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                The medication essentially makes your pancreas "smarter," responding appropriately to blood sugar levels rather than continuously releasing insulin regardless of need.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">2. Suppresses Glucagon Secretion</h3>
              <p className="text-muted-foreground leading-relaxed">
                Glucagon is a hormone that tells your liver to release stored glucose. In type 2 diabetes, glucagon levels are often inappropriately high, causing your liver to dump sugar into your bloodstream even when you don't need it.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                Semaglutide reduces glucagon secretion, particularly after meals, preventing these unhelpful glucose surges. This dual action—increasing insulin when needed and decreasing glucagon when not—provides powerful blood sugar control.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">3. Slows Gastric Emptying</h3>
              <p className="text-muted-foreground leading-relaxed">
                By slowing how quickly food leaves your stomach, semaglutide reduces post-meal blood sugar spikes. This mechanism also contributes to increased fullness and reduced appetite, addressing the common challenge of weight gain with diabetes.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">4. Improves Insulin Sensitivity</h3>
              <p className="text-muted-foreground leading-relaxed">
                The weight loss achieved with semaglutide significantly improves insulin sensitivity—your body's cells become more responsive to insulin. This creates a positive cycle: better blood sugar control leads to weight loss, which leads to even better blood sugar control.
              </p>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Clinical Evidence: The SUSTAIN Trials</h2>
              <p className="text-muted-foreground leading-relaxed">
                The SUSTAIN clinical trial program, comprising 10 major studies with over 10,000 participants, established semaglutide as one of the most effective diabetes treatments available.
              </p>
              
              <h3 className="text-2xl font-semibold mb-3 text-foreground">SUSTAIN 6: Cardiovascular Outcomes</h3>
              <p className="text-muted-foreground leading-relaxed">
                This landmark cardiovascular outcomes trial followed 3,297 people with type 2 diabetes at high cardiovascular risk for over 2 years. Results showed:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death)</li>
                <li>39% reduction in non-fatal stroke</li>
                <li>26% reduction in non-fatal heart attack</li>
                <li>36% reduction in new or worsening kidney disease</li>
              </ul>
              <p className="text-muted-foreground leading-relaxed mt-3">
                These results led to semaglutide receiving FDA approval for reducing cardiovascular risk in adults with type 2 diabetes and established heart disease.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">SUSTAIN 1-5 & 7: Glycemic Control</h3>
              <p className="text-muted-foreground leading-relaxed">
                These trials compared semaglutide to placebo and various active diabetes medications. Key findings:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Superior A1C reduction compared to sitagliptin, exenatide, dulaglutide, and canagliflozin</li>
                <li>Greater proportion of patients reaching A1C goal of less than 7%</li>
                <li>Significant weight loss (4-7 kg on average) compared to weight gain or neutral effects with comparators</li>
                <li>Improvements in blood pressure and lipid profiles</li>
              </ul>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Dosing for Diabetes Management</h2>
              <p className="text-muted-foreground leading-relaxed">
                For type 2 diabetes, semaglutide (marketed as Ozempic) uses different dosing than for weight loss alone:
              </p>
              
              <h3 className="text-2xl font-semibold mb-3 text-foreground">Standard Diabetes Dosing Schedule</h3>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li><strong>Weeks 1-4:</strong> 0.25 mg once weekly (not a therapeutic dose, for GI tolerability)</li>
                <li><strong>Week 5 onward:</strong> Increase to 0.5 mg once weekly</li>
                <li><strong>Optional increase:</strong> After at least 4 weeks, can increase to 1 mg once weekly if additional glycemic control needed</li>
                <li><strong>Maximum dose:</strong> 2 mg once weekly (if more control needed and 1 mg tolerated well)</li>
              </ul>

              <p className="text-muted-foreground leading-relaxed mt-4">
                Most patients achieve excellent diabetes control at 0.5 mg or 1 mg weekly. The 2 mg dose is reserved for those needing additional A1C reduction and is actually the same dose used for weight management in Wegovy (though labeled as 2.4 mg in that formulation).
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Oral Semaglutide (Rybelsus)</h3>
              <p className="text-muted-foreground leading-relaxed">
                Semaglutide is also available as a daily oral tablet (Rybelsus) for those who prefer not to inject:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Start at 3 mg daily for 30 days</li>
                <li>Increase to 7 mg daily</li>
                <li>Can further increase to 14 mg daily if needed</li>
                <li>Must be taken on empty stomach, 30 minutes before food/drink</li>
              </ul>
              <p className="text-muted-foreground leading-relaxed mt-3">
                Injectable semaglutide is generally more effective than oral, but Rybelsus provides an option for those with strong injection aversion.
              </p>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Combining with Other Diabetes Medications</h2>
              
              <h3 className="text-2xl font-semibold mb-3 text-foreground">Metformin</h3>
              <p className="text-muted-foreground leading-relaxed">
                Semaglutide and metformin work through different mechanisms and combine synergistically. Most patients continue metformin when starting semaglutide. This combination is safe and highly effective, with complementary actions on blood sugar control.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">SGLT2 Inhibitors</h3>
              <p className="text-muted-foreground leading-relaxed">
                Combining semaglutide with SGLT2 inhibitors (like empagliflozin or dapagliflozin) provides multiple cardiovascular and renal benefits. Both classes independently reduce cardiovascular risk, making this combination particularly valuable for high-risk patients.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Insulin</h3>
              <p className="text-muted-foreground leading-relaxed">
                Many patients can reduce or discontinue insulin after starting semaglutide. However, some may need to continue both medications. If combining:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Reduce insulin dose by 20-30% when starting semaglutide to avoid hypoglycemia</li>
                <li>Monitor blood sugars closely during the first few weeks</li>
                <li>Work with your provider to adjust insulin dosing as semaglutide takes effect</li>
                <li>Risk of hypoglycemia increases when combining—more frequent monitoring essential</li>
              </ul>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Sulfonylureas</h3>
              <p className="text-muted-foreground leading-relaxed">
                Sulfonylureas (glipizide, glyburide, glimepiride) can be combined with semaglutide but increase hypoglycemia risk. Many providers prefer to discontinue sulfonylureas when starting semaglutide, as semaglutide often provides superior control without the hypoglycemia risk.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">DPP-4 Inhibitors</h3>
              <p className="text-muted-foreground leading-relaxed">
                Do NOT combine semaglutide with DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin). Both work on the GLP-1 system, and combining provides no additional benefit while increasing side effect risk. Discontinue DPP-4 inhibitors before starting semaglutide.
              </p>
            </section>

            <Card className="p-6 bg-primary/5 border-primary/20">
              <h3 className="text-xl font-semibold mb-4 flex items-center text-foreground">
                <AlertCircle className="mr-2 h-5 w-5 text-primary" />
                Real Patient Success: A1C Improvements
              </h3>
              <div className="space-y-4 text-muted-foreground">
                <div className="border-b border-border pb-3">
                  <p className="font-medium">Baseline A1C: 9.2%</p>
                  <p>After 6 months on 1 mg semaglutide: 6.8%</p>
                  <p className="text-sm italic">Lost 32 pounds, discontinued sulfonylurea</p>
                </div>
                <div className="border-b border-border pb-3">
                  <p className="font-medium">Baseline A1C: 8.5%</p>
                  <p>After 6 months on 0.5 mg semaglutide: 6.4%</p>
                  <p className="text-sm italic">Lost 28 pounds, reduced insulin by 50%</p>
                </div>
                <div>
                  <p className="font-medium">Baseline A1C: 10.1%</p>
                  <p>After 6 months on 2 mg semaglutide: 7.2%</p>
                  <p className="text-sm italic">Lost 45 pounds, eliminated basal insulin completely</p>
                </div>
              </div>
            </Card>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Managing Side Effects</h2>
              <p className="text-muted-foreground leading-relaxed">
                Side effects are similar whether using semaglutide for diabetes or weight loss. The most common are gastrointestinal:
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Nausea</h3>
              <p className="text-muted-foreground leading-relaxed">
                Affects 15-20% of patients, usually mild and improving over time. Management strategies:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Eat smaller, more frequent meals</li>
                <li>Avoid high-fat, greasy foods</li>
                <li>Stay well-hydrated</li>
                <li>Ginger tea or ginger supplements may help</li>
                <li>Take medication before bedtime to sleep through peak nausea</li>
              </ul>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Diarrhea or Constipation</h3>
              <p className="text-muted-foreground leading-relaxed">
                GI motility changes can cause either. Increase fiber gradually, stay hydrated, and consider probiotics. If persistent, discuss with your provider—they may adjust your dose.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Hypoglycemia Risk</h3>
              <p className="text-muted-foreground leading-relaxed">
                Low when semaglutide is used alone, but increases when combined with insulin or sulfonylureas. Monitor blood sugars more frequently when starting treatment, and have fast-acting glucose available.
              </p>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Long-Term Benefits Beyond Blood Sugar</h2>
              
              <h3 className="text-2xl font-semibold mb-3 text-foreground">Cardiovascular Protection</h3>
              <p className="text-muted-foreground leading-relaxed">
                The SUSTAIN 6 trial demonstrated significant cardiovascular risk reduction. For people with type 2 diabetes and established cardiovascular disease, semaglutide is now recommended as a preferred treatment option by both the American Diabetes Association and European Association for the Study of Diabetes.
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Kidney Protection</h3>
              <p className="text-muted-foreground leading-relaxed">
                Diabetic kidney disease affects up to 40% of people with diabetes. Semaglutide demonstrated significant reductions in the progression of diabetic kidney disease in clinical trials, including reductions in:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>New or worsening kidney disease by 36%</li>
                <li>Progression to macroalbuminuria (significant protein in urine)</li>
                <li>Need for continuous renal replacement therapy</li>
              </ul>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Weight Loss Impact on Diabetes</h3>
              <p className="text-muted-foreground leading-relaxed">
                The average weight loss of 5-10% seen with semaglutide in diabetes trials has profound effects beyond A1C reduction:
              </p>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Reduced need for other diabetes medications</li>
                <li>Improved blood pressure</li>
                <li>Better lipid profiles</li>
                <li>Reduced fatty liver disease</li>
                <li>Decreased joint pain and improved mobility</li>
                <li>Enhanced quality of life and diabetes self-management</li>
              </ul>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Who Should Consider Semaglutide for Diabetes?</h2>
              
              <h3 className="text-2xl font-semibold mb-3 text-foreground">Ideal Candidates</h3>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Type 2 diabetes not adequately controlled on metformin alone</li>
                <li>Those with established cardiovascular disease or high cardiovascular risk</li>
                <li>People with diabetic kidney disease</li>
                <li>Patients who struggle with weight management</li>
                <li>Those wanting to reduce or eliminate insulin therapy</li>
                <li>Patients seeking once-weekly medication for convenience</li>
              </ul>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Not Recommended For</h3>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Type 1 diabetes (not a replacement for insulin)</li>
                <li>Diabetic ketoacidosis (requires insulin)</li>
                <li>Personal or family history of medullary thyroid carcinoma</li>
                <li>Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)</li>
                <li>History of pancreatitis (relative contraindication, discuss with provider)</li>
                <li>Pregnant or breastfeeding women</li>
                <li>Severe gastroparesis</li>
              </ul>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Monitoring Your Progress</h2>
              <p className="text-muted-foreground leading-relaxed">
                Regular monitoring ensures optimal results and safety:
              </p>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Blood Sugar Monitoring</h3>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>More frequent checks when starting or adjusting dose</li>
                <li>Pre-meal and bedtime readings particularly important if on insulin</li>
                <li>Continuous glucose monitors (CGMs) highly valuable for real-time feedback</li>
              </ul>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">A1C Testing</h3>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Check every 3 months until A1C stable at goal</li>
                <li>Then every 6 months if well-controlled</li>
                <li>Goal typically less than 7%, but individualized based on age, complications, life expectancy</li>
              </ul>

              <h3 className="text-2xl font-semibold mb-3 text-foreground">Other Important Tests</h3>
              <ul className="list-disc pl-6 space-y-2 text-muted-foreground">
                <li>Kidney function (eGFR and urine albumin) annually</li>
                <li>Lipid panel annually</li>
                <li>Liver function tests baseline and as needed</li>
                <li>Diabetic eye exam annually</li>
                <li>Blood pressure at each visit</li>
              </ul>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">Cost and Access Considerations</h2>
              <p className="text-muted-foreground leading-relaxed">
                For diabetes treatment, insurance coverage for semaglutide (Ozempic) is typically better than for weight loss alone (Wegovy). Most insurance plans cover Ozempic as a diabetes medication, though prior authorization may be required.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                Medicare Part D covers semaglutide for diabetes, and co-pays vary significantly based on your specific plan. Some manufacturers offer patient assistance programs that can reduce out-of-pocket costs to as low as $25 per month for eligible patients.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                Compounded semaglutide provides a more affordable alternative for those without insurance coverage or with high co-pays. At Trimi, we offer compounded semaglutide starting at just $249/month, making this transformative therapy accessible to more patients.
              </p>
            </section>

            <section>
              <h2 className="text-3xl font-bold mb-4 text-foreground">The Bottom Line</h2>
              <p className="text-muted-foreground leading-relaxed">
                Semaglutide represents a paradigm shift in type 2 diabetes management. Beyond superior blood sugar control, it offers cardiovascular and kidney protection, significant weight loss, and the convenience of once-weekly dosing.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                The medication works through multiple complementary mechanisms, addressing the root causes of diabetes rather than just treating symptoms. For many patients, semaglutide enables them to reduce or eliminate other diabetes medications, simplifying their treatment regimen while improving outcomes.
              </p>
              <p className="text-muted-foreground leading-relaxed">
                If you have type 2 diabetes, especially if you're not at goal on your current medications or struggling with weight management, semaglutide deserves serious consideration. The evidence is clear: this medication can transform diabetes management and significantly reduce long-term complications.
              </p>
            </section>

            <TopicClusterNav
              pillarPage={clusterNav.pillarPage}
              hubPage={clusterNav.hubPage}
              relatedArticles={clusterNav.relatedInCluster}
              topic="Health Conditions"
            />

            <section className="mt-12 p-6 bg-muted/50 rounded-lg border border-border">
              <h3 className="text-lg font-semibold mb-3 text-foreground">Medical Disclaimer</h3>
              <p className="text-sm text-muted-foreground leading-relaxed">
                This article is for informational purposes only and does not constitute medical advice. Diabetes management must be individualized and supervised by qualified healthcare providers. Never adjust your diabetes medications without consulting your provider. Individual responses to semaglutide vary, and the information provided here should not replace professional medical guidance. Always discuss your specific situation, medical history, diabetes complications, and treatment goals with your healthcare provider before starting semaglutide or making any changes to your diabetes treatment plan.
              </p>
            </section>

            <section className="mt-8">
              <h3 className="text-lg font-semibold mb-3 text-foreground">References</h3>
              <ol className="list-decimal pl-6 space-y-2 text-sm text-muted-foreground">
                <li>Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.</li>
                <li>Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286.</li>
                <li>Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260.</li>
                <li>Ahrén B, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-blind, Phase 3a, Randomized Trial. Diabetes Care. 2017;40(9):1092-1100.</li>
                <li>American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1).</li>
                <li>Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.</li>
              </ol>
            </section>
          </div>

          <TopicClusterNav
            topic="Semaglutide for Diabetes"
            relatedArticles={clusterNav.relatedInCluster}
            hubPage="/blog/semaglutide"
          />

          <div className="mt-12 flex flex-col sm:flex-row gap-4">
            <Link to="/treatments/semaglutide" className="flex-1">
              <Button size="lg" className="w-full">
                Start Semaglutide Treatment
              </Button>
            </Link>
            <Link to="/blog" className="flex-1">
              <Button size="lg" variant="outline" className="w-full">
                More Articles
              </Button>
            </Link>
          </div>
        </article>
      </main>

      <Footer />
    </>
  );
};

export default SemaglutideForDiabetes;